Topics

Conserved Elements Vaccine for HIV

19:00 EST 6 Dec 2017 | NIH

The development of an effective HIV vaccine has been an ongoing area of research. High variability in HIV-1 virus strains, however,  represents a major challenge.  Ideally, an effective candidate vaccine would provide protection against the majority of clades of HIV.  Two major hurdles to overcome are immunodominance and sequence diversity. Researchers at the National Cancer Institute (NCI) have developed a vaccine that overcomes these major hurdles by utilizing a strategy that identifies conserved regions of the virus and exploits them for use in a targeted therapy.

NCI researchers used conserved elements (CEs) of the polypeptide Gag as an immunogenic composition to induce an immune response to HIV-1.  This invention is based, in part, on the discovery that the administration of one or more polypeptides comprising seven CEs of HIV Gag provides a robust immune response compared to administration of a full-length Gag protein.  In vivo studies of rhesus macaques vaccinated with variants of these constructs elicited strong, cellular T-cell and humoral antibody immune responses. The Gag-specific antibody responses were high titer and cross-clade. 

A robust increase in immunity was observed when rhesus macaques were subjected to a prime-boost protocol.  Rhesus macaques primed with Gag-CE DNA and boosted with full length Gag had increased cellular and humoral responses.  The CE vaccines described in this invention are potential prophylactic and therapeutic HIV vaccines.

IC: 
NCI
NIH Ref. No.: 
E-132-2012
Advantages: 
  • Addresses two key hurdles faced by current HIV vaccines: sequence diversity of HIV and immunodominance.
  • Induces cross-clade cellular and humoral responses. 
Applications: 
  • Prophylactic and therapeutic vaccines for HIV-1 infection 
Development Status: 

Clinical

Updated On: 
Jun 28, 2019
Date Published: 
Thursday, December 7, 2017
Provider Classifications: 
Publications: 
Patent Application: 
PCT/US2013/028932
EP2820035 A1
15/235,430
Patent Number: 
9,415,099
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
NCI
NCI
Inventor Lab URL: 
https://ccr.cancer.gov/Vaccine-Branch/george-n-pavlakis
https://ccr.cancer.gov/Vaccine-Branch/barbara-k-felber
LPM FIrst Name: 
John
LPM Last Name: 
Hewes
Inv Is lead: 
LPM Phone: 
240-276-5515
LPM Suffix: 
Ph.D.
LPM Organization: 
NCI - National Cancer Institute
DTDT Classification: 
Vaccines
DTDT Description: 
Vaccines
Pat Filing Date: 
2013-03-04
2013-03-04
2016-08-12
Patent Issue Date: 
2016-08-16
Publication Link: 
https://www.ncbi.nlm.nih.gov/pubmed/28678607
https://www.ncbi.nlm.nih.gov/pubmed/27733554
Publication Caption: 
PMID
PMID
Publication Title: 

Hu X., et al. 

Hu X., et al.

Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

Licensing and research collaboration

E Number Only: 
E-132-2012
Inventor First Name: 
George
Barbara
James
Inventor Last Name: 
Pavlakis
Felber
Mullins

Original Article: Conserved Elements Vaccine for HIV

NEXT ARTICLE

More From BioPortfolio on "Conserved Elements Vaccine for HIV"

Quick Search